-+ 0.00%
-+ 0.00%
-+ 0.00%

BRIEF-Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China

Reuters·08/12/2026 21:17:43

Please log in to view news